European drug regulator is criticised over patient representatives’ conflicts of interestBMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c3349 (Published 21 June 2010) Cite this as: BMJ 2010;340:c3349
- Philip Wilson
Representatives of patients’ groups sat on the European Medicines Agency’s management board without declaring their ties to the drug industry, an open letter sent to the agency said last week. The agency described the situation as an honest mistake.
The letter, dated 18 June, was sent by the Medicines in Europe Forum and the International Society of Drug Bulletins to the agency’s executive director, Thomas Lönngren.
It was prompted by a report from the Corporate Europe Observatory, a campaign group that aims to expose the power of corporate …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial